ART initiates clinical trials of optical breast imaging system
ART, Advanced Research Technologies Inc., is undertaking clinical trials at Toronto's Princess Margaret Hospital as part of its North American pivotal study for the SoftScan optical breast imaging system.
"This study will give access to an important pool of volunteer patients from hospitals such as Mount Sinai Hospital and Princess Margaret Hospital, and contribute to the success of clinical trials now underway across Canada and the U.S.," said Micheline Bouchard, president and CEO of ART. "The completion of pivotal trials will open the way for the commercialization of this molecular imaging technology whose potential applications continue to grow," Bouchard added.
Through participation in this study, Princess Margaret Hospital is joining other renowned medical centers such as the Cedars Breast Clinic of the McGill University Health Centre, the Centre Hospitalier de l'Université de Montréal, the Central Alberta Medical Imaging Services and the Massachusetts General Hospital, in bringing the SoftScan device to market. This study actually is the final stage necessary before SoftScan, an optical breast imaging system designed to improve the diagnosis and treatment of breast cancer, can be sold commercially.
"This study will give access to an important pool of volunteer patients from hospitals such as Mount Sinai Hospital and Princess Margaret Hospital, and contribute to the success of clinical trials now underway across Canada and the U.S.," said Micheline Bouchard, president and CEO of ART. "The completion of pivotal trials will open the way for the commercialization of this molecular imaging technology whose potential applications continue to grow," Bouchard added.
Through participation in this study, Princess Margaret Hospital is joining other renowned medical centers such as the Cedars Breast Clinic of the McGill University Health Centre, the Centre Hospitalier de l'Université de Montréal, the Central Alberta Medical Imaging Services and the Massachusetts General Hospital, in bringing the SoftScan device to market. This study actually is the final stage necessary before SoftScan, an optical breast imaging system designed to improve the diagnosis and treatment of breast cancer, can be sold commercially.